DOI: 10.36347/sajp.2020.v09i08.001

Pages: 234-238

Background: Metabolic syndrome is a multiplex risk factor that arises from hyperglycemia /insulin resistance accompanied with abnormal fat function &central obesity& possibility to develop diabetes mellitus type-2, atherosclerosis & various diseases. Aim of study: To determine the effect of ropinirole & metformin on glycemic Parameters, insulin sensitivity and lipid profile associated with metabolic syndrome. Patients and methods: The present study was performed in diabetic and endocrine center from May 2016 to march 2018. Ninety female patients with metabolic syndrome participate in this study .They were allocated to three groups (each group contain 30 patients) first group put on diet restriction physical exercise only. Second group received metformin 750mg extended release orally once daily at night with diet restriction & physical exercise. Third group received ropinirole 0.25 mg orally after meal in morning with diet restriction & physical exercise. The duration of the study extended to 12 weeks. Blood samples were taken from each patient at zero time to determine base line level & after 12 weeks of treatment. The measured parameters were WBC, BMI, FBS, FI, HOMA-IR, Hb A1c, TC, TG, HDL, LDL. Results: Showed highly significant lowering effect of both ropinirole & metformin on the levels of the all parameters except HDL with high significant elevation, at the mean time all the parameters of the control were significantly changed. Conclusion: Both drugs improve glycemic parameters, insulin sensitivity and lipid profile in metabolic syndrome but metformin is slightly more powerful on these parameters.